<?xml version='1.0' encoding='utf-8'?>
<document id="24252882"><sentence text="Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal." /><sentence text="Rhabdomyolysis precipitated by multitherapy is most frequently described during statin treatment, due to impairment of statin clearance by drugs sharing cytochrome P450 biotransformation pathway" /><sentence text=" Modulation of membrane transporters for drug efflux, operated by substrates, can also affect drugs' tissue levels" /><sentence text=" We report rhabdomyolysis in an elderly patient, in multitreatment with different potentially myotoxic medications, taking place seven months after atorvastatin discontinuation"><entity charOffset="148-160" id="DDI-PubMed.24252882.s4.e0" text="atorvastatin" /></sentence><sentence text=" Affected by ischaemic heart disease, arterial hypertension and dementia-related behaviour disturbances, the patient was receiving angiotensin 2-receptor inhibitors, beta-blockers, vasodilators, diuretics, salycilates, allopurinol, proton pump inhibitors, antipsychotics and antidepressants"><entity charOffset="219-230" id="DDI-PubMed.24252882.s5.e0" text="allopurinol" /></sentence><sentence text=" He had taken atorvastatin for 14 years, with constantly normal creatine-kinase plasma levels"><entity charOffset="14-26" id="DDI-PubMed.24252882.s6.e0" text="atorvastatin" /></sentence><sentence text=" Two months after addition of the antianginal drug ranolazine, creatine-kinase mildly increased and atorvastatin was withdrawn"><entity charOffset="51-61" id="DDI-PubMed.24252882.s7.e0" text="ranolazine" /><entity charOffset="63-71" id="DDI-PubMed.24252882.s7.e1" text="creatine" /><entity charOffset="100-112" id="DDI-PubMed.24252882.s7.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24252882.s7.e0" e2="DDI-PubMed.24252882.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24252882.s7.e0" e2="DDI-PubMed.24252882.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24252882.s7.e0" e2="DDI-PubMed.24252882.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24252882.s7.e1" e2="DDI-PubMed.24252882.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24252882.s7.e1" e2="DDI-PubMed.24252882.s7.e2" /></sentence><sentence text=" Nonetheless, creatine-kinase progressively rose, with severe weakness and rhabdomyolysis developing seven months later" /><sentence text=" Muscle biopsy showed a necrotizing myopathy with no inflammation or autoimmune changes" /><sentence text=" After ranolazine withdrawal, creatine-kinase and myoglobin returned to normal levels and strength was restored"><entity charOffset="7-17" id="DDI-PubMed.24252882.s10.e0" text="ranolazine" /></sentence><sentence text=" Several psychotropic and cardiovascular medications prescribed to the patient share either cytochrome P450 biotransformation and permeability-glycoprotein efflux transport" /><sentence text=" In the event of cardiovascular/neuropsychiatric polypharmacy in geriatric patients, the risk of muscle severe adverse effects from pharmacokinetic drug-drug interaction should be considered beyond the direct myotoxicity of statins" /><sentence text="" /></document>